Why Dana-Farber’s Enhertu biomarker study could change metastatic breast cancer diagnostics
Dana-Farber’s new study highlights Ignite Proteomics in Enhertu response prediction. Read what this could mean for metastatic breast cancer care.
What TAG1’s Lead-212 supply deal with Dana-Farber reveals about the future of radiopharmaceutical oncology
TAG1 and Dana-Farber partner to expand Lead-212 access for targeted alpha therapies. Discover what this means for radiopharmaceutical oncology innovation.
What the Akeso–INOVIO immunotherapy collaboration signals for the future of glioblastoma clinical research
Akeso and INOVIO test cadonilimab plus INO-5412 in the INSIGhT glioblastoma trial. Explore what this immunotherapy strategy could mean for GBM research.
Why 10x Genomics is betting on CLIA lab certification to advance spatial diagnostics in oncology
Find out how 10x Genomics and Dana-Farber aim to transform cancer diagnostics using spatial biology and single cell profiling for real-world clinical decisions.